| | Presentation | Media | Date |
| Erik Penser – Interview with CSO Johan Sandin about AlzeCure’s projects.
| |
|
December 13, 2022
|
| Interview at Finwire news with CEO Martin Jönsson (The presentation will be held in Swedish).
| |
|
December 12, 2022
|
| Erik Penser – Interview with Martin Jönsson about the ongoing Rights Issue.
| |
|
December 6, 2022
|
| Rights Issue presentation with CEO Martin Jönsson at Erik Penser Bank.
|
|
|
December 6, 2022
|
| CEO Martin Jönsson presents AlzeCure at BioStock.
| |
|
December 5, 2022
|
| AlzeCure’s CEO Martin Jönsson presents at BioStock in connection with a new share issue, December 5, 2022.
| |
|
December 5, 2022
|
| Quantitative EEG results from a multiple ascending dose study. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
| AC-0027875, a novel gamma-secretase modulator. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
| Preclinical characterization of ACD856. Scientific presentation at the CTAD conference nov 29- 2dec, 2022.
|
|
|
November 30, 2022
|
| CEO Martin Jönsson interviewed at Redeye Life Sciences Day on the company’s positive development & plans, as well as about the proposed rights issue in December and the positive progress in the Alzheimer’s market, and what this means for AlzeCure.
| |
|
November 24, 2022
|
| Martin Jönsson presented at Life Science Investor Conference the company’s successes and ongoing projects, as well as the company’s new share issue.
| |
|
November 23, 2022
|
| CEO Martin Jönsson presents AlzeCure’s progress and ongoing projects, as well as the company’s proposed share issue. (English)
| |
|
November 17, 2022
|
| Aktiespararna’s event with AlzeCure on November 16, 2022 – Martin Jönsson, AlzeCure’s CEO, presented the company’s progress and ongoing projects, as well as the company’s planned share issue. The presentation was held in Swedish.
| |
|
November 16, 2022
|
| CEO Martin Jönsson presented an update on our Pain management projects at Redeye Theme: Neurology on October 12.
| |
|
October 12, 2022
|
| CEO Martin Jönsson presented the company’s latest developments at Redeye Theme: Neurology on October 12, 2022.
| |
|
October 12, 2022
|
| The Trk-PAM ACD856 improves mitochondrial function and increases BDNF levels in primary cortical neurons; Scientific presentation at the ISMND Conference, Athens, October 10-12, 2022.
|
| |
October 11, 2022
|
| Analgesic and Anti-inflammatory Effects of Small Molecule Negative Allosteric Modulators of TrkA; Scientific presentation at the IASP Conference, Toronto, September 19-23, 2022.
|
| |
September 22, 2022
|
| Martin talks about the latest developments for AlzeCure including the phase 2 study with ACD 440 against neuropathic pain, the new positive clinical results with NeuroRestore ACD 856, our new patent and the new results with the pain project TrkA-NAM. (Swedish).
| |
|
September 12, 2022
|
| Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the latest clinical progress (Swedish).
| |
|
September 1, 2022
|
| Results From a Multiple Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors AAIC July – Aug 2022.
|
|
|
July 31, 2022
|
| Watch the interview with Aktiespararna at Finwire with AlzeCure’s CEO Martin Jönsson. (Swedish).
| |
|
July 1, 2022
|
| AlzeCure – Interview at Redeye with CEO Martin Jönsson about the phase II study with ACD440. (Swedish).
| |
|
June 23, 2022
|
| AlzeCure at Redeye Growth Day.
| |
|
June 2, 2022
|
| CEO Martin Jönsson Presenting at Redeye Growth Day.
| |
|
May 23, 2022
|
| The use of PathHunter cell lines to discover modulators of Trk-receptors. From HTS to phase 1; Scientific presentation at the ELRIG Conference, Gothenburg, May 10-12, 2022.
|
| |
May 10, 2022
|
| AlzeCure – Alzheimer event at Redeye (Swedish).
| |
|
May 3, 2022
|
| Identification of a positive modulator of neurotrophin recptors with memory-enhancing effects and improved mitochondrial function; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research.
|
| |
April 21, 2022
|
| Preliminary Results From a Single Ascending Dose Study in Healthy Volunteers of ACD856, a Positive Modulator of Neurotrophin Trk-Receptors; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm,
|
| |
April 21, 2022
|
| Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease; Scientific presentation at the 2nd Swedish Meeting for Alzheimer Research, Stockholm.
|
| |
April 21, 2022
|
| A positive modulator of neurotrophin receptors improves cognition and mitochondrial function; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022.
| |
|
March 17, 2022
|
| NeuroRestore – Preliminary results from a Single Ascending Dose study in healthy volunteers of ACD856, a positive modulator of Neurotrophin Trk-receptors; Scientific presentation at the AD/PD conference, Barcelona, March 15-20, 2022
|
|
|
March 15, 2022
|
| Watch the Analysisguide’s interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the future (in Swedish).
| |
|
March 14, 2022
|
| CEO Martin Jönsson is interview by BioStock on the company’s latest developments, including the ongoing rights issue.
| |
|
March 14, 2022
|
| CSO Johan Sandin explains the science behind AlzeCure’s project portfolio and what distinguishes it from other pharma companies (Swedish).
| |
|
March 14, 2022
|
| See CEO Martin Jönsson and CSO Johan Sandin, present upcoming events in the company and the ongoing issue (Swedish).
| |
|
March 11, 2022
|
| Watch the interview with AlzeCure’s CEO Martin Jönsson – about events in the company and the ongoing issue (Swedish).
| |
|
March 9, 2022
|
| AlzeCure – New presentation at Penser (Swedish).
| |
|
February 24, 2022
|
| Latest newsflow (Swedish).
| |
|
February 3, 2022
|
| CEO Martin Jönsson presents at Aktiespararna (Swedish).
| |
|
January 31, 2022
|
| Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, Scientific presentation at 11th Pharmaceutical Profiling meeting, January 27, 2022.
|
| |
January 27, 2022
|
| Alzstatin – Development of novel ?-secretase modulators for the treatment of Alzheimer’s disease.
|
| |
January 27, 2022
|
| Alzstatin – Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease (Text only).
|
| |
January 27, 2022
|
| AlzeCure Pharma – Kapitalmarknadsdag.
| |
|
January 18, 2022
|
